A kind of lymphoma drug is also effective for treatment of liver cancer

Associate Professor, University of Tokyo Kato Naoya led research team has announced that they found in animal experiments, a therapeutic T-cell lymphoma (lymphoma) existing drugs used for liver cancer has a therapeutic effect. After using this medication, liver cell surface protein will increase as the immune cells attack identified and thus more easily damaged. This discovery will help to develop new treatments for cancer immunotherapy.

Liver cells infected with hepatitis B, hepatitis C virus or the emergence of cancer, stress response occurs (stress) when there will be a cell surface protein called MICA enhances expression. The MICA protein is known as NK cells, immune cells target, NK cells subsequently begin to attack.

When the research team had previously investigated approximately 1,500 liver cancer patients and about 6,000 healthy human genetic variation, found that these patients had suffered from liver cancer caused by hepatitis viruses, the expression of MICA little, causing risk of liver cancer increased to 2 times . The expressions of MICA protein about 55% of patients with liver cancer are few.

The research team investigated the US Food and Drug Administration (FDA) approved 640 kinds of existing drugs, to find out whether there are drugs that increase the expression of MICA protein. It was found that if the added hepatocytes in vitro for the treatment of cutaneous T-cell lymphoma (cutaneous T-cell lymphoma) of "histone deacetylase inhibitors" (histone deacetylase inhibitor), the expression of MICA protein will increase to 30 times.

The team believe that this is due to the "histone deacetylase inhibitor" adds the ability to activate the transcription factor gene function, resulting in a more MICA protein.

The team of human hepatoma cells transplanted into mice subcutaneously injected discovered histone deacetylase inhibitor after injection with no one group of mice as compared to the latter half of the 30 days of tumor size. The team believes that histone deacetylase inhibitors, although not directly attack cancer cells, but it can attack the immune cells gather.

In the future, the team prepared to apply existing drugs cannot play a role in liver cancer patients as the object to carry out clinical trials to verify the histone deacetylase inhibitor effect. The team believes that if and after in vitro activation of immune cells re-injected into the body of existing cancer immunotherapy and use, it is possible to enhance the therapeutic effect.

In addition, the drug treatment of liver cancer, sorafenib, is to help prevent the expansion of the tumor, and the "histone deacetylase inhibitor" actively helps destroy liver cancer cells, it is expected to receive better treatment.

Currently, for removing hepatitis C virus, Sofosbuvir's results were better, but still not able to clear the hepatitis B virus and prevent cirrhosis develop liver cancer drug, the research team believes that "histone deacetylase inhibitor” may also play a role.

We recommend this for you: http://www.cusabio.com/ELISA-Kit/Fish-Apolipoprotein-EAPOE-ELISA-kit-1035336.html